Marcus Gerlach

Medicine · Health Sciences

10h-index302citations74works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(51), HER2/EGFR in Cancer Research(44), Peptidase Inhibition and Analysis(15), Radiopharmaceutical Chemistry and Applications(14), Click Chemistry and Applications(8)

Publications74 total

Supplementary Figure S6 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Table 1 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Table 3 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Table 5 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Methods from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Data from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S2 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S4 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S5 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Table 4 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S7 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Table 2 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S3 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure S1 from TUB-010, a Novel Anti-CD30 Antibody–Drug Conjugate Based on Tub-Tag Technology, Widens the Therapeutic Window by Reducing Toxicity While Maintaining High Efficacy
2026Open Access
Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025Open Access
page 1 of 4Next →

Frequent Co-authors

Dominik Schumacher(43), Marc‐André Kasper(42), Jonas Helma(41), Saskia Schmitt(37), Isabelle Mai(35), Philipp Cyprys(35), Annette M. Vogl(35), Philipp Ochtrop(33), Christian P. R. Hackenberger(27), Paul Machui(27), Sarah Herterich(27), Swetlana Wunder(15), Heinrich Leonhardt(14), Danila Hauswald(12), Annabel Kitowski(12), Olivier Marcq(12), Pamela A. Trail(12), Björn Hock(12), Günter R. Fingerle-Rowson(11), Natascia Leonardi(10)